(RTTNews) - Merck & Co., Inc. (MRK) announced positive results from the Phase 3 KEYNOTE-C93 trial, evaluating KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.